[Ip-health] $1.8 Billion Sanofi Vaccine Contract Contains International Reference Pricing Clause, Preserves Standard IP and Data Rights

kathryn ardizzone kathryn.ardizzone at keionline.org
Wed Dec 2 08:40:06 PST 2020


Link: https://www.keionline.org/34776

*$1.8 Billion Sanofi Vaccine Contract Contains International Reference
Pricing Clause, Preserves Standard IP and Data Rights*

Posted on December 2, 2020 by Kathryn Ardizzone

The contract awarding Sanofi Pasteur (“Sanofi”) 1.8 billion U.S. taxpayers’
dollars for the development and manufacture of a COVID-19 vaccine was
posted in the Department of Health and Human Services (HHS) Electronic
Reading Room on November 30, 2020. Overall, the agreement is more favorable
to the public in terms of intellectual property (IP) and data than the
majority of U.S. government (USG) COVID-19 contracts available for
inspection in the public domain. Unlike the majority of those contracts,
the Sanofi agreement does not appear to weaken standard, legally prescribed
government rights in IP and data. The contract also includes an
international referencing pricing clause and provides the government a
broad license to access or have a third party access the IP, data,
know-how, and FDA approval or regulatory filings needed to manufacture the
vaccine in certain instances in which Sanofi fails to ensure adequate
supply. [SNIP].


-- 
Kathryn Ardizzone, Esq.
Counsel
Knowledge Ecology International
1621 Connecticut Avenue NW, Suite 500
Washington, DC 20009
kathryn.ardizzone at keionline.org
(202) 332-2670


More information about the Ip-health mailing list